首页> 外文期刊>Expert opinion on biological therapy >Therapeutic evaluation of a microbioartificial liver with recombinant HepG2 cells for rats with hepatic failure
【24h】

Therapeutic evaluation of a microbioartificial liver with recombinant HepG2 cells for rats with hepatic failure

机译:重组HepG2细胞对人工肝的治疗对肝衰竭大鼠的治疗评价

获取原文
获取原文并翻译 | 示例
       

摘要

Background: HepG2/(ArgI+OTC)4 (previously constructed) is a recombinant human liver cell line with a strong ability to reduce ammonia in vitro. However, its application value ex vivo has not been investigated. Objectives: To examine the efficacy of HepG2/(ArgI+OTC)4 cells in a micro-bioartificial liver (micro-BAL) device for application ex vivo. Methods: A simple micro-BAL device containing a microbioreactor and a small-type peristaltic pump was installed. The rats with hepatic failure were randomly divided into three groups (n = 10) and were treated with different micro-BAL loaded HepG2/(ArgI+OTC)4 cells, HepG2 cells and control (without cells), respectively. Changes in the liver and kidney function of the rats were determined before and after the treatment. The lifespan of the rats were observed and recorded. Results: Despite the difference in survival time between experimental groups of rat model was not statistically significant, the capacity of HepG2/(ArgI+OTC)4 cells treatment group for tolerance and detoxifying ammonia was increased much more than that of HepG2 cells (p < 0.05), and other biochemical indicators of HepG2/(ArgI+OTC)4 cells treatment group were also better than that of HepG2 cells treatment group (p < 0.05). Conclusions: HepG2/(ArgI+OTC)4 cells can provide a better biological support for rats with hepatic failure in a short period of time, and they may be used as a convenient and useful choice for further cell material research of BAL.
机译:背景:HepG2 /(ArgI + OTC)4(先前构建)是具有强大的体外还原氨能力的重组人肝细胞系。然而,尚未对其离体的应用价值进行研究。目的:检查HepG2 /(ArgI + OTC)4细胞在微生物人工肝(micro-BAL)装置中离体应用的功效。方法:安装了一个装有微生物反应器和小型蠕动泵的简单微型BAL装置。肝衰竭大鼠随机分为三组(n = 10),分别用不同的微BAL加载的HepG2 /(ArgI + OTC)4细胞,HepG2细胞和对照组(无细胞)治疗。在治疗之前和之后确定大鼠肝和肾功能的变化。观察并记录大鼠的寿命。结果:尽管大鼠模型实验组之间的生存时间差异无统计学意义,但HepG2 /(ArgI + OTC)4细胞治疗组对氨氮和排毒的耐受性却比HepG2细胞增加了更多(p < 0.05),HepG2 /(ArgI + OTC)4细胞治疗组的其他生化指标也优于HepG2细胞治疗组(p <0.05)。结论:HepG2 /(ArgI + OTC)4细胞可在短时间内为肝衰竭大鼠提供更好的生物学支持,可作为进一步研究BAL的方便和有用的选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号